Tamer M Fouad
Cairo University
H-index: 23
Africa-Egypt
Top articles of Tamer M Fouad
123P Updated safety of perioperative durvalumab for resectable NSCLC in AEGEAN
ESMO Open
2024/3/1
Perioperative durvalumab for resectable non–small-cell lung cancer
New England Journal of Medicine
2023/11/2
Tamer M Fouad
H-Index: 18
OA12. 06 Neoadjuvant Durvalumab+ Chemotherapy Followed by Adjuvant Durvalumab in Resectable EGFR-mutated NSCLC (AEGEAN)
Journal of Thoracic Oncology
2023/11/1
OA12. 05 Surgical Outcomes with Neoadjuvant Durvalumab+ Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC (AEGEAN)
Journal of Thoracic Oncology
2023/11/1
AEGEAN: A phase 3 trial of neoadjuvant durvalumab+ chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC
Zentralblatt für Chirurgie-Zeitschrift für Allgemeine, Viszeral-, Thorax-und Gefäßchirurgie
2023/8
Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab+ chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC
Cancer Research
2023/5/29
Tamer M Fouad
H-Index: 18
Design and rationale for a phase III, double-blind, placebo-controlled study of neoadjuvant durvalumab+ chemotherapy followed by adjuvant durvalumab for the treatment of …
Clinical Lung Cancer
2022/5/1
Stephanie Jones
H-Index: 8
Tamer M Fouad
H-Index: 18
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2‐Positive Inflammatory and Noninflammatory Breast Cancer …
The oncologist
2020/6/1
Co-Authors
